All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. View funders.

2018-09-25T08:42:24.000Z

Duvelisib has been approved by the FDA for R/R CLL or SLL

Sep 25, 2018
Share:

Bookmark this article

On 24 September 2018, the US Food and Drug Administration announced the approval of duvelisib (COPIKTRA) for the treatment of adult patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after two prior lines of therapy.

Duvelisib is the first oral dual inhibitor of phosphoinositide-3-kinase-delta (PI3K-δ) and PI3K-γ being developed by Verastem. The approval follows data from the phase III DUO trial (NCT02004522) comparing duvelisib to ofatumumab, in which the results were presented at the American Society of Hematology (ASH) in December 2017. Associate Professor Nicole Lamanna discusses the outcomes of the DUO trial in an interview with Lymphoma Hub at ASH 2017, watch here.

Study Highlights

  • 196 patients were randomized to receive either duvelisib (n = 95) or ofatumumab (n = 101). 
  • The estimated mean progression-free survival assessed by an independent review committee was 16.4 months for duvelisib and 9.1 months for ofatumumab (HR 0.40)
  • The overall response rate was 78% for duvelisib and 39% for ofatumumab 

The FDA has also accelerated the approval of duvelisib for the treatment of adult patients with R/R follicular lymphoma (FL) after two prior lines of therapy. 

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
26 votes - 5 days left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox